Genetic Diseases

A 23andMe "increased likelihood" glaucoma result is not a diagnosis. Here is what 263 risk loci, MYOC, and a real eye exam actually mean.

Two APOL1 risk variants on a 23andMe test raise real kidney risk, but most carriers stay healthy. Here is what the science actually shows.

PCOS is polygenic, not weight-driven. A 2025 study found 94 risk loci. Here is what a 23andMe score means versus a real diagnosis.

Bone density is polygenic, not one broken gene. A 2026 study of 223,818 women turned scores into screening ages of 60, 65, or 69 — research, not a guideline.

Preeclampsia is polygenic, not a single-gene disease. What the 2023 multi-ancestry GWAS, a 4 percent baseline risk, and the aspirin guidelines actually say.

A 523,366-person genome study says sleep apnea genetics is not simply obesity genetics. Here is what a consumer score can predict, and what only a sleep study can.

A 181,446-case genome study made the AFib score real. Framingham shows what it means in people: 22 to 48 percent lifetime risk, and about seven years of delay.

One LAMB3 variant makes a person a carrier, not a patient. The sourced per-pregnancy math, the 48 percent chip gap, and what regulators approved.

A 23andMe report flagged you as a PEX1 carrier for Zellweger spectrum disorder? A research-grounded, plain-English look at what "carrier" really means, the honest odds, testing, and US/Canada rights.

A single PKHD1 variant on a 23andMe report usually makes you a healthy carrier, not a patient. Here is the research-grounded difference, in plain English.